Program
DA-5223
A development code. Also written as “DA-5223-F”, “DA-5223-M” and “DA-5223(Fasting)”.
Its studies are led by Dong-A ST.
Furthest: phase 1, since May 28, 20253 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dong-A ST | 30 open or running | phase 1since May 28, 2025 | May 28, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 28, 2025First studies: 2 phase 1 studies in Healthy AdultFirst studyNCT07007533, NCT07007520
- Jun 1, 2026Phase 1 study in Healthy AdultNCT07633691 · 12 enrolled · South Korea
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07633691Healthy Adult · South Korea | 1 | Completed | Jun 23, 2026 | 12 |
| NCT07007533Healthy Adult · South Korea | 1 | Completed | Jul 17, 2025 | 38 |
| NCT07007520Healthy Adult · South Korea | 1 | Withdrawn | Nov 2025 | 0 |
How it is read
Names in the registry
- “DA-5223-F”, 1 entry
- “DA-5223-M”, 1 entry
- “DA-5223(Fasting)”, 1 entry
- “DA-5223(Fed)”, 1 entry
- “DA-5223-R”, 1 entry
Codes read as this program: DA5223.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.